Loading in 2 Seconds...
Loading in 2 Seconds...
According to the latest report published by Credence Research, Inc. “Antibody Drug Conjugate\nMarket– (Drug Type – Adcetris and Kadcyla): Market Growth, Future Prospects and Competitive\nAnalysis, 2016-2023,” the market was valued at USD 1.3 Bn in 2015
“Antibody Drug Conjugate Market- Growth, Share, Opportunities,
Competitive Analysis, and Forecast 2016 – 2023”
According to the latest report published by Credence Research, Inc. “Antibody Drug Conjugate
Market– (Drug Type – Adcetris and Kadcyla): Market Growth, Future Prospects and Competitive
Analysis, 2016-2023,” the market was valued at USD 1.3 Bn in 2015, and is expected to reach USD
29.3 Bn by 2022, expanding at a CAGR of 41.7% from 2016 to 2024.
Browse the full report Antibody Drug Conjugate Market: Market Growth, Future Prospects
Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs
such as chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers
with liable bonds. They combine the unique targeting property of monoclonal antibodies with the
cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased
tissues. Currently marketed drugs suffers from various stipulations like low potency, lack of
specificity and adverse effects. This has forced the pharmaceutical and research companies to
develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates
have overcome these scenarios and improve the medical conditions. The currently marketed antibody
drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche) followed by
several Antibody Drug Conjugates (ADCs) in pipeline showcase the potential for innovations in this
In base year 2015, North America accounted for the largest market in the antibody drug conjugate
market due to the presence of major pharmaceutical companies working on the development of
antibody drug conjugate drugs. Moreover, one of the prime reason of North America’s dominance in
the antibody drug conjugates market is the fast-track approval and commercialization of ADCs in the
region as compared to other geographical regions. Europe held the second largest market for
antibody drug conjugates market. Kadcyla, one of the two drugs that are marketed currently is
manufactured by the Europe based pharmaceutical giant, Roche. Additionally, Europe was the second
region after where the commercialization of the ADCs were approved on a fast-track basis. Asia
pacific is anticipated to be the fastest growing segment in the antibody drug conjugate market due to
the approval of ADCs in Japan, China.
Market Competition Assessment:
The antibody drug conjugate market currently possesses only two companies having their drugs
marketed. However, many companies have their molecules in the clinical development stage which
hit market during the forecast period. The companies include Immunomedics, Spirogen, Pfizer,
Roche/Genentech, Oxford BioTherapeutics, and Others.
Browse the full Antibody Drug Conjugate Market - Growth, Future Prospects and Competitive Analysis,
2017 – 2025 report at http://www.credenceresearch.com/report/antibody-drug-conjugate-market
Credence Research is a worldwide market research and counseling firm that serves driving organizations,
governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most imperative objectives. Over almost
a century, we've manufactured a firm extraordinarily prepared for this task.
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US